Time filter

Source Type

Li S.,Cancer Research Institute of Ganzhou | Xie C.,Ganzhou Tumor Hospital | Guo S.,Ganzhou Tumor Hospital | Kang Z.,Ganzhou Tumor Hospital
Chinese Journal of Clinical Oncology | Year: 2013

Objective: This study aims to evaluate the efficacy and adverse reactions of pemetrexed (PEM) combined with nedaplatin (NDP) in elderly patients with advanced lung adenocarcinoma. Methods: A total of 32 cases of patients, aged more than 70 years, with advanced lung adenocarcinoma were treated with PEM and NDP chemotherapy as the initial treatment. PEM (500 mg/m2) was administrated by intravenous infusion, 10 min, dl; NDP (80 mg/m2) intravenous infusion, dl, 21 d for a cycle of treatment. Results: In the evaluation of the efficacy and adverse reactions of 32 patients, the CR had 0 case, PR had 14 cases, SD had 13 cases, PD 5 cases, the effective rate was 43.8% (14/32), median time to progression was 6.6 months, median survival time was 13.1 months, and one year survival rate was 57.3%. Major adverse events were anemia (68.8%; 22/32), nausea and vomiting (62.5%; 20/32), leukopenia (59.4%; 19/32), platelets decreased by (40.6%; 13/32), constipation (21.9%; 7/32), hair loss (12.5%; 4/32), and elevated transaminase (9.4%; 3/32); no chemotherapy-related death occurred. Conclusion: Patients more than 70 years of age with advanced lung cancer can tolerate chemotherapy for nedaplatin (NDP) combined with pemetrexed (PEM). Moreover, the majority of patients can benefit from the effective treatment with mild adverse reactions.

Loading Cancer Research Institute of Ganzhou collaborators
Loading Cancer Research Institute of Ganzhou collaborators